SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline

Abstract We analyzed 21 676 residual specimens from Ontario, Canada collected March–August 2020 to investigate the effect of antibody decline on SARS-CoV-2 seroprevalence estimates. Testing specimens orthogonally using Abbott (anti-nucleocapsid) and Ortho (anti-spike) assays, seroprevalence estimate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infectious diseases 2021-04, Vol.223 (8), p.1334-1338
Hauptverfasser: Bolotin, Shelly, Tran, Vanessa, Osman, Selma, Brown, Kevin A, Buchan, Sarah A, Joh, Eugene, Deeks, Shelley L, Allen, Vanessa G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract We analyzed 21 676 residual specimens from Ontario, Canada collected March–August 2020 to investigate the effect of antibody decline on SARS-CoV-2 seroprevalence estimates. Testing specimens orthogonally using Abbott (anti-nucleocapsid) and Ortho (anti-spike) assays, seroprevalence estimates were 0.4%–1.4%, despite ongoing disease activity. The geometric mean concentration (GMC) of antibody-positive specimens decreased over time (P = .015), and GMC of antibody-negative specimens increased over time (P = .0018). Association between the 2 tests decreased each month (P 
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiaa796